212 related articles for article (PubMed ID: 34620840)
1. BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability.
Tang X; Guo M; Ding P; Deng Z; Ke M; Yuan Y; Zhou Y; Lin Z; Li M; Gu C; Gu X; Yang Y
Signal Transduct Target Ther; 2021 Oct; 6(1):361. PubMed ID: 34620840
[TBL] [Abstract][Full Text] [Related]
2. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.
Gu C; Wang W; Tang X; Xu T; Zhang Y; Guo M; Wei R; Wang Y; Jurczyszyn A; Janz S; Beksac M; Zhan F; Seckinger A; Hose D; Pan J; Yang Y
Mol Cancer; 2021 Jun; 20(1):84. PubMed ID: 34090465
[TBL] [Abstract][Full Text] [Related]
3. BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.
Yang Y; Gu C; Luo C; Li F; Wang M
Med Oncol; 2015 Mar; 32(3):81. PubMed ID: 25698537
[TBL] [Abstract][Full Text] [Related]
4. Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.
Koyuncu D; Sharma U; Goka ET; Lippman ME
Breast Cancer Res Treat; 2021 Jan; 185(2):331-341. PubMed ID: 33130993
[TBL] [Abstract][Full Text] [Related]
5. The FOXM1/BUB1B signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma.
Ma Q; Liu Y; Shang L; Yu J; Qu Q
Oncol Rep; 2017 Dec; 38(6):3367-3375. PubMed ID: 29039578
[TBL] [Abstract][Full Text] [Related]
6. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
Zhang Z; Zhang G; Gao Z; Li S; Li Z; Bi J; Liu X; Li Z; Kong C
BMC Cancer; 2017 Dec; 17(1):861. PubMed ID: 29246203
[TBL] [Abstract][Full Text] [Related]
8. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.
Zhou W; Yang Y; Xia J; Wang H; Salama ME; Xiong W; Xu H; Shetty S; Chen T; Zeng Z; Shi L; Zangari M; Miles R; Bearss D; Tricot G; Zhan F
Cancer Cell; 2013 Jan; 23(1):48-62. PubMed ID: 23328480
[TBL] [Abstract][Full Text] [Related]
9. BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
Sekino Y; Han X; Kobayashi G; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
Oncology; 2021; 99(4):240-250. PubMed ID: 33588420
[TBL] [Abstract][Full Text] [Related]
10. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma.
Qin Y; Zhang S; Deng S; An G; Qin X; Li F; Xu Y; Hao M; Yang Y; Zhou W; Chang H; Qiu L
Leukemia; 2017 May; 31(5):1123-1135. PubMed ID: 27857131
[TBL] [Abstract][Full Text] [Related]
12. Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma.
Scintu M; Vitale R; Prencipe M; Gallo AP; Bonghi L; Valori VM; Maiello E; Rinaldi M; Signori E; Rabitti C; Carella M; Dallapiccola B; Altomare V; Fazio VM; Parrella P
Cancer Lett; 2007 Sep; 254(2):298-307. PubMed ID: 17498870
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to
Lee E; Pain M; Wang H; Herman JA; Toledo CM; DeLuca JG; Yong RL; Paddison P; Zhu J
Cancer Res; 2017 Oct; 77(20):5518-5529. PubMed ID: 28855212
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma.
Dong S; Huang F; Zhang H; Chen Q
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30765611
[TBL] [Abstract][Full Text] [Related]
15. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic values of spindle checkpoint protein BUB1B in triple negative breast cancer].
Zhang PC; Zhong XR; Zheng H; Li L; Chen F; Shen MJ; Li YJ; Chen H; Cao SY; Bu H; Ye F
Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):645-649. PubMed ID: 34078054
[No Abstract] [Full Text] [Related]
17. BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK.
Tian JH; Mu LJ; Wang MY; Zeng J; Long QZ; Guan B; Wang W; Jiang YM; Bai XJ; Du YF
Anticancer Agents Med Chem; 2020; 20(9):1140-1146. PubMed ID: 31893996
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer.
Yamamoto Y; Matsuyama H; Kawauchi S; Matsumoto H; Nagao K; Ohmi C; Sakano S; Furuya T; Oga A; Naito K; Sasaki K
Oncology; 2006; 70(3):231-7. PubMed ID: 16837776
[TBL] [Abstract][Full Text] [Related]
19. Twist1 induces chromosomal instability (CIN) in colorectal cancer cells.
Khot M; Sreekumar D; Jahagirdar S; Kulkarni A; Hari K; Faseela EE; Sabarinathan R; Jolly MK; Sengupta K
Hum Mol Genet; 2020 Jun; 29(10):1673-1688. PubMed ID: 32337580
[TBL] [Abstract][Full Text] [Related]
20. Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents.
Komura K; Inamoto T; Tsujino T; Matsui Y; Konuma T; Nishimura K; Uchimoto T; Tsutsumi T; Matsunaga T; Maenosono R; Yoshikawa Y; Taniguchi K; Tanaka T; Uehara H; Hirata K; Hirano H; Nomi H; Hirose Y; Ono F; Azuma H
Oncogene; 2021 Oct; 40(43):6210-6222. PubMed ID: 34545188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
